BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2920953)

  • 1. A study of the monoclonal antibody OC 125 to diagnose malignant ovarian tumors.
    Li XG; Chen DX; Schwartz PE; Yang Z
    Gynecol Oncol; 1989 Mar; 32(3):327-30. PubMed ID: 2920953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of CA 125 monoclonal antibody to monitor patients with ovarian cancer.
    Kudlacek S; Schieder K; Kölbl H; Neunteufel W; Nowotny C; Breitenecker G; Biegelmayer G; Vetterlein M; Fürlinger B; Micksche M
    Gynecol Oncol; 1989 Dec; 35(3):323-9. PubMed ID: 2480931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of monoclonal antibody OC 125 in gynecological oncology].
    Wu AR; Wang EY; Wang XX; Jia XH; Li L
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the CA 125 assay in the management of ovarian cancer.
    Niloff JM
    Oncology (Williston Park); 1988 Aug; 2(8):67-76. PubMed ID: 3275060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritoneal tuberculosis, large ovarian thecoma, and an elevated serum CA 125 level mimicking ovarian cancer.
    Hoffman MS
    J Fla Med Assoc; 1989 Apr; 76(4):388-9. PubMed ID: 2551992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
    Chen DX; Schwartz PE; Li FQ
    Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer. CA 125 as a tumor marker. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
    Kaesemann H; Caffier H; Hoffmann FJ; Crombach G; Würz H; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G
    Klin Wochenschr; 1986 Sep; 64(17):781-5. PubMed ID: 3463828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative measurement of cancer antigen 125 (CA 125) in the differential diagnosis of ovarian tumors.
    Mogensen O; Mogensen B; Jakobsen A; Sell A
    Acta Oncol; 1989; 28(4):471-3. PubMed ID: 2789822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between serum CA 125 and CA 19-9 assays and tissular OC 125 and 1116NS 19-9 reactivity in malignant and benign ovarian tumors.
    Gadducci A; Ciancia EM; Malagnino G; De Luca F; Campani D; Ferdeghini M; Facchini V; Pingitore R; Fioretti P
    Eur J Gynaecol Oncol; 1992; 13(4):346-54. PubMed ID: 1516586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The value of CA 125 determination in the serum of patients with ovarian cancer].
    Bartel U; Johannsen B; Elling D
    Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
    van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
    Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
    Sevelda P; Salzer H; Dittrich C; Spona J
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
    Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
    Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High CA-125 values in miliary tuberculosis and ascites].
    Klein M; Marczewski A; Rosen A; Beck A
    Wien Klin Wochenschr; 1989 Dec; 101(24):870-1. PubMed ID: 2623880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA 125 in the diagnosis of pelvic masses.
    Mogensen O; Mogensen B; Jakobsen A
    Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1187-90. PubMed ID: 2767108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
    Menczer J; Ben-Baruch G; Moran O; Lipitz S
    Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
    Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
    Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Prontera C; Moretti L; Pellagatta L; Bianchi R; Fioretti P
    J Nucl Biol Med (1991); 1991; 35(1):33-7. PubMed ID: 1657201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
    Miladinović D; Paunović R; Paunković N
    Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.